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Squamous cell carcinoma of the nasal cavity: A descriptive analysis of cases from the 




This paper aims to provide contemporary epidemiological data on squamous cell 
carcinoma (SCC) of the nasal cavity, which represents a rare type of head and neck 
cancer. 
Design, Setting & Participants 
A descriptive analysis of people with nasal cavity SCC treated with curative intent from 
the Head and Neck 5000 study; a multicentre clinical cohort study of people from the UK 
with head and neck cancer. People with tumours of the nasopharynx, paranasal sinuses 
and other sub-sites of the head and neck were excluded. 
Main outcome measures 
Demographic data and treatment details are presented for all participants. The main 
outcomes were overall survival and survival according to categories of characteristics 
(e.g. smoker vs non-smoker); these were explored using Kaplan-Meier plots.  
Results 
Thirty people with nasal cavity SCC were included in the study, of which most were male 
(67%) and current or ex-smokers (70%). The majority (70%) presented with early 
stage (T1/2, N0) tumours. Cervical lymph node metastases at presentation were rare, 
occurring in only one person. Nine people died during the follow up period (30%). 
Worse survival outcomes were seen in people with moderate or severe co-morbidities.  
Conclusions 
This paper provides epidemiological data on nasal cavity SCC in the UK. Patterns of 
disease and survival outcomes are described, identifying high-risk groups. Further 
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Malignant tumours of the nasal cavity are rare in the UK, with an incidence of less than 1 
per 100,000 per annum in England [1]. When considered together with tumours of the 
paranasal sinuses, they represent 3% of all head and neck malignancies [2]. In all 
populations, nasal cavity cancer has a male preponderance, but the incidence varies by 
geographical location, with the highest rates seen in African and Asian populations [3, 
4].  
Unlike other sub-sites within the head and neck, there is wide histological variation in 
nasal cavity tumours. The majority of tumours are squamous cell carcinoma (SCC), but a 
range of other tumour types are also reported, including melanoma, adenocarcinoma, 
salivary gland-type carcinoma, olfactory neuroblastoma and sinonasal undifferentiated 
carcinoma (SNUC) [4].  
Smoking is an established risk factor for the development of nasal cavity SCC, and more 
recently, infection with oncogenic types of human papillomavirus (HPV) has also been 
shown to play a role [4, 5]. Although an association between occupational exposure to 
hardwood dust and adenocarcinoma of the paranasal sinuses has been identified, its 
relationship to tumours of the nasal cavity is yet to be defined [6].   
Epidemiological data for SCC of the nasal cavity are limited due to the low incidence of 
nasal cavity cancer and the varied histopathology of tumours. In the majority of studies, 
nasal cavity cancers are presented alongside those of the paranasal sinuses, despite 
differences in tumour biology, epidemiology, and treatment response [2].  
Head & Neck 5000 is a multicentre prospective cohort study of people with a new 
diagnosis of head and neck cancer [7, 8]. This paper uses data from this study to 






The methodology for the Head and Neck 5000 study has been previously described [7]. 
In brief, between April 2011 and December 2014, a total of 5,511 people with head and 
neck cancer were recruited from 76 centres. People with lymphoma, skin cancer and 
secondary tumours were not included in the Head and Neck 5000 study. Lifestyle, 
quality of life questionnaires and clinical information were collected at baseline (pre-
treatment) and at 4 and 12 months after treatment. Biological samples including 
Formalin Fixed Paraffin Embedded (FFPE) biopsy tissue, blood and saliva were also 
obtained pre-treatment. Written consent was obtained from all participants. 
 
Case definition 
People with a clinical diagnosis recorded by the study centre as nasal cavity cancer (ICD-
10 C30, 'nasal cavity') were identified. Pathology reports of individual cases were 
checked to verify tumour site and subtype. Only cases with consistent clinical and 
pathological data were included. Tumours of the paranasal sinuses, nasopharynx, skin 
and other sub-sites within the head and neck were excluded. Treatment intent was 
identified from pre-treatment data capture forms.  
Socio-demographic variables 
Age to the nearest year at consent to the study was recorded.  Smoking status was 
collected through self-completed questionnaires at baseline. For analysis, smoking data 
were aggregated into a binary variable; ‘never smoker’ or ‘current or former smoker’. 
 
Clinical characteristics 
Tumour TNM stage (Union for International Cancer Control 7th edition)[9] was obtained 
from pre-treatment data capture forms.  For the purposes of analysis, stage was 
expressed as a binary variable. Stage I or II (T1 or T2, N0) tumours were defined as 
‘early stage’, and stage III or IV (T3 or T4, N+) tumours were defined as ‘late stage’. 
 
Comorbidity was determined using the Adult Comorbidity Evaluation 27 (ACE 27) [10] 
score obtained from pre-treatment data capture forms. The highest ranked single 
ailment determined the overall score (excluding newly diagnosed head and neck 
cancer).  Scoring ranged from 0, denoting no comorbidity, to 3 indicating severe 
decompensation. For analysis the comorbidities were grouped into none/mild, and 
moderate/severe. 
 
Treatment modality was identified from 4-month data capture forms. For the purposes 
of analysis, people were grouped according to primary treatment modality (surgery or 
radiotherapy) +/- adjuvant treatment.  
 
The primary measure of human papillomavirus (HPV) status was serological response 
to HPV antibodies using a glutathione S-transferase multiplex assay carried out at the 
German Cancer Research Center (DKFZ) in Heidelberg, Germany [11]. Seropositivity 





Follow up  
Study participants were flagged with the UK Health and Social Care Information Centre, 
which provided regular notification of the date and cause of death of participants who 
had died. Survival time was measured from study enrolment until either death or the 
end of the most recent follow-up period (25th August 2018). 
 
Statistical analysis  
 
Analysis was performed using STATA (Release 15, StataCorp, TX, USA). Characteristics 
of people with SCC of the nasal cavity were summarised using percentages or medians 
with interquartile ranges as appropriate. Pairwise associations between the 
characteristics were assessed using Fisher's exact tests. Overall survival and survival 
according to each of the categories of the characteristics was explored using Kaplan-
Meier plots and log rank tests. Due to the rarity of SCC of the nasal cavity, the sample 




The Head & Neck 5000 study was approved by the National Research Ethics Committee 
(South West Frenchay Ethics Committee, reference 10/H0107/57, 5th November 2010). 
The analysis of nasal cavity cancer from Head & Neck 5000 was approved by the 
University of Bristol Faculty of Health Science Research Ethics Committee on 28th April 
2016 (reference 35501). 




Description of sample 
Of the 5,511people who fulfilled the eligibility criteria for the Head and Neck 5000 
study, 4,744 had pathology reports available, and 61 were recorded as having nasal 
cavity cancer.  Review of histology showed that six cases did not have a pathology report 
to confirm the diagnosis, and six had indeterminate pathology or site of origin. These 
were excluded from the study. The remainder consisted of 30 squamous cell 
carcinomas, 10 adenocarcinomas, six melanomas, and three olfactory neuroblastomas.  
Characteristics for the 30 people with SCC of the nasal cavity are shown in Table 1.  The 
median age at consent to the study was 66 years (interquartile range 56 to 75 years). 
Two thirds were male, and just over two thirds were smokers (which included 26% 
current smokers and 44% former smokers). Just over a quarter had moderate or severe 
comorbidities. Most people (70%) had small (T1 or T2) tumours, and only one person 
had lymph node metastasis (clinical stage N1). None had distant metastases.  Only two 
people (7% of the 29 with data recorded) were seropositive for HPV16. The primary 
treatment consisted of primary surgery for half and primary radiotherapy for the other 
half; full details of the treatment type is given in Table 1.  No one received neck 
dissection.  Everyone underwent treatment with curative intent. 
 
Associations between characteristics 
Pairwise associations between age, gender, smoking status, comorbidities, tumour TNM 
stage and treatment are shown in Table 2. There was statistical evidence for an 
association between being a non-smoker and having surgery (p=0.03), and to a lesser 
degree between not having comorbidities and late stage tumours (p=0.07).  Possible 
associations between not smoking and late stage tumours (p=0.2), and younger people 
being female (p=0.2) were also identified.  There were no associations between any of 
the other pairs of characteristics (p ≥0.4).      
Associations with survival 
Nine of the 30 people (30%) died, the median duration of follow up was 34 months 
(range 7 to 67 months [IQR 18 to 54 months]) for those that died, and 54 months (range 
45 to 74 months [IQR 50 to 66 months]) for those that were still alive at the end of the 
study. Kaplan-Meier analysis of overall survival is shown in Figure 1. Estimates for 
overall survival and survival according to age, gender, smoking status, comorbidities, 
tumour TNM stage and treatment are shown in Supplementary Table 1. 
 
There was statistical evidence that survival was worse for people with comorbidities 
(p=0.01) (Figure 2).  Survival was worse for males, those who did not have surgery and 
those with early stage tumours, but there was no statistical evidence for these 
differences (p=0.4 for all) (Figure 2).  There were no differences between the age groups 
or smoking categories (p=0.9 for both).  Comparisons between categories of 
characteristics were made at 45 months as this is minimum duration of follow up 







This study provides a descriptive analysis of people with nasal cavity SCC: a rare type of 
head and neck cancer. The study showed that nasal cavity SCC is predominantly a 
disease of male smokers, although tumours were also seen in females and in non-
smokers. The majority of primary cancers were staged as T1 or T2, indicating that the 
tumours at presentation remained limited to the nasal cavity. Regional lymph node 
metastases at presentation were rare; only one patient had metastatic disease in a single 
cervical lymph node. Worse survival outcomes were seen in people with moderate or 




Tumour stage in nasal cavity SCC 
 
The findings from this study are consistent with findings from previous studies 
suggesting that lymph node metastases are uncommon at diagnosis in nasal cavity SCC, 
occurring in between 0-6% of people [4, 13-15]. Becker and colleagues reported 39 
cases of nasal cavity SCC over a 16-year period, half of which underwent neck dissection. 
From a total of 305 dissected lymph nodes, only a single node contained metastatic SCC, 
leading the authors to conclude that treatment of the N0 neck is only indicated in high 
risk cases [4].  
 
Although the incidence of lymph node metastases at diagnosis is low, regional 
recurrence has been reported in up to 18% of people with nasal cavity SCC (95% CI, 
13%-23%) [16]. This may be explained by the observation that lymph node metastases 
from mid-facial SCCs are often delayed [17]. Another explanation may be the presence of 
occult micrometastases in regional lymph nodes, which may not be identified on routine 
histopathological examination without serial step sectioning [18]. Finally, the high rate 
of regional recurrence may occur because elective treatment of the neck (either surgery 
or radiotherapy) is not performed in the context of no clinical or radiological nodal 
disease. Whatever the explanation, the high rate of regional recurrence mandates close 





In this study, overall survival estimates were 83% (95% CI: 65%-93%) and 69% (95% 
CI: 46%-84%) at 3 years and 5 years respectively. Due to small numbers at longer 
follow-up durations in this study, confidence intervals are wide, however, the findings 
are consistent with other recent analyses.  Ho and Coman described a series of 
seventeen people with cancer of the nasal septum and found that three-year survival 
was 82% [19]. In a meta-analysis of people with nasal cavity SCC, Scurry and colleagues 
reported a 5-year overall survival (63%; 95% CI, 62%-64%). These figures are however 
derived from studies published between 1974 and 2000, and therefore may not reflect 
current treatment outcomes.  
 
Co-morbidity is an established indicator for poor prognosis in head and neck cancer, 
and the results from this study support the suggestion that co-morbidities confer an 
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adverse prognosis in people with nasal cavity cancer [20].  Other associations with 
survival were weak, but there was a suggestion of reduced survival in people treated 
with radiotherapy compared to surgery. Although the radiotherapy group contained a 
higher proportion of smokers than the surgery group, there was no association between 
smoking and survival. Furthermore no association was observed between co-morbidity 
and treatment modality or tumour stage and treatment modality.  
 
Previous studies have reported that people undergoing non-surgical treatment for nasal 
cavity cancer may have worse rates of overall survival and loco-regional control than 
those undergoing surgery [4, 14, 15, 21]. The effect size observed in those studies varied 
widely, but was broadly comparable to the results of this study. For example, Fornelli 
and colleagues described 32 people with nasal cavity SCC, 23 received primary surgery, 
and nine underwent primary radiotherapy. With a mean follow up duration of 4.4 years 
(range 9 months to 13 years) overall survival was 43% in the surgery group and 33% in 
the radiotherapy group [15]. In the study by Mendenhall et al., 5 year overall survival 
was 73% for people treated with primary surgery, 38% for those treated by primary 
radiotherapy [21]. Although the effect size in that study was large, it included tumours 
of varied histology and those from the paranasal sinuses, so may not be directly 
comparable to our study.  
 
Although these studies suggest improved outcomes following surgical management of 
nasal cavity cancer, much of the results come from historical series. The last two 
decades have seen improvements in both surgical techniques (e.g. endoscopic surgical 
approaches, pre-operative assessment and optimisation) and non-surgical treatment 
modalities (e.g. intensity-modulated radiotherapy & concomitant platinum-based 
chemotherapy). The association between treatment modality and survival therefore 
requires further examination and may be an area for future research.  
 
Paradoxically, higher all cause mortality was seen in people with early stage tumours 
than those with late stage tumours. This finding is at odds with previous studies, and 
may be explained by the higher proportion of people in the early stage group with 
moderate or severe co-morbidities (Table 2) or it could represent a chance finding given 





This study describes the features of nasal cavity cancer in a small group of people from 
the UK, and is comparable in size to other case series of nasal cavity SCC. Although 
exposure to passive smoke was not measured, almost a quarter of those included in the 
study were non-smokers, suggesting that the pathogenesis and risk factors for nasal 
cavity cancer may be incompletely understood. In this study only two people had 
evidence of oncogenic HPV infection but this was based on seroconversion rather than 
measures of HPV in the tissue. Seroconversion is known to be a good marker of HPV 
driven oropharyngeal SCC but its ability to detect HPV driven tumours outside the 
oropharynx is unclear. Recent results from a US study using a real-time multiplex PCR 
assay to identify fifteen high-risk HPV subtypes from paraffin-preserved tumour tissue, 
indicated evidence of HPV infection in 62% [5].  Larger prospective cohort studies of 
people with nasal cavity cancer are required to better describe the risk factors 
associated with disease, the clinical characteristics of cases and factors associated with 
better survival. 
 
As previously mentioned, a possible association between treatment modality and 
survival requires further study in the context of modern treatment paradigms. Given the 
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low incidence of nasal cavity SCC pooling of existing studies and meta-analysis may 
allow a further assessment of this relationship and help decide whether further larger 
observational studies are warranted.  
 
 
Strengths and weaknesses of this study  
This study reports epidemiological data on a rare and highly specific group of people 
with nasal cavity cancer. In all cases anatomical sub-site and histological type were 
confirmed by a pathologist, ensuring a high degree of accuracy. Furthermore, cases are 
drawn from a large national cohort that recruited participants between 2011 and 2014, 
meaning that treatment regimens represent current best practice in both radiotherapy 
and surgery. The results are broadly consistent with those from other studies that 
reported data collected over the course of several decades [2, 4, 15, 21].  
 
The main weakness of this study is the small sample size. This reflects the low incidence 
of nasal cavity SCC [1]. Therefore many of our findings need to be interpreted with 
caution. An additional weakness is that smoking data were missing for seven people and 
co-morbidity data were missing for one. Co-morbidity information was obtained by local 
clinical teams, but by contrast, smoking data were derived from self-administered 
questionnaires, completed by participants and returned to the study team. This may 




This study provides a descriptive analysis of people with SCC of the nasal cavity in the 
UK. The results indicate the characteristics of affected individuals, the pattern of tumour 
staging and associations between demographic data and survival. The results have also 
highlighted areas for further research in this rare subgroup of people with head and 
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